SimBioSys secures third US FDA 510(k) clearance for its TumorSight Viz to advance AI─powered precision surgery in breast ...
SimBioSys, a clinical AI company leveraging spatial biophysics to drive precision in breast cancer treatment, announced its third US FDA 510(k) clearance for TumorSight Viz 1.3. The clearance expands the platform's ability to convert standard breast …